History
The company's origins date from 1912, when Atlas Chemical Industries was founded by demerger from DuPont in Wilmington, Delaware, United States, in 1912. Subsequently, Atlas Chemical Industries acquired Stuart Pharmaceuticals (founded by Arthur Hanisch in Pasadena, California, U.S., in 1941) in 1961 before itself being bought by ICI in 1972. In 1993 ICI demerged this pharmaceuticals business, as well as its agrochemicals and specialties businesses, to form Zeneca Group plc.
Astra AB was founded in 1913 by 400 doctors and apothecaries in Södertälje, Sweden. In 1949 the company developed Xylocaine, a local anesthetic.[clarification needed] In 1994 the company formed a joint venture with Merck to market Losec, an ulcer-treatment drug.
In 1999 Astra AB and Zeneca Group plc merged to form AstraZeneca plc.
In 2005 the company announced an arrangement with Astex for the discovery, development and commercialisation of novel small molecule inhibitors of protein kinase B for use as anti-cancer agents. In the same year it announced a collaboration with Avanir for research and licensing in the area of Reverse Cholesterol Transport (RCT) enhancing compounds for the treatment of cardiovascular disease. It also announced an alliance with Schering AG for research and licensing in the area of selective glucocorticoid receptor agonists (SEGRAs). It also announced that it had become a Diamond Member of the Pennsylvania Bio commerce organization.
In 2006, following a collaborative relationship begun in 2004, AstraZeneca acquired Cambridge Antibody Technology in a deal worth £702 million[clarification needed].
Also in 2006 it formed an alliance with Abbott Laboratories in relation to Crestor and TriCor, commencing that year and extending to at least 2009.
In 2007 it reported that it had entered into an alliance with Bristol-Myers Squibb to form a global collaboration to develop and commercialise two investigational drugs (saxagliptin and dapagliflozin) beginning from 2007.
Also in 2007 AstraZeneca acquired MedImmune for about $15.2 billion. AstraZeneca consolidated its biologics portfolio in MedImmune and Cambridge Antibody Technology which was rebranded to create a dedicated biologics division known as 'MedImmune'
Operations
AstraZeneca develops, manufactures, and sells pharmaceuticals to treat disorders in the gastrointestinal, cardiac and vascular, neurological and psychiatric, infection, respiratory, pathological inflammation and oncology areas.
The corporate headquarters are in London, United Kingdom, the research and development (R&D) headquarters are in Södertälje. Major R&D centres are located in India, Sweden, the U.K. and the U.S. AstraZeneca has a large R&D centre in Cheshire, U.K.; this centre acts as one of Zeneca's main hubs.
AstraZeneca has laboratories in a large country estate on the east side of the A34 road north of the Monk's Heath crossroads in Cheshire in England.


